SCHOLAR ROCK RECEIVES FDA FAST TRACK DESIGNATION FOR APITEGROMAB FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) PROGRAM AS PARTICIPANT DOSING COMMENCES IN PHASE 2 FORGE TRIAL

Reuters · 2d ago

Please log in to view news